Navigation Links
Cloned receptor paves way for new breast and prostate cancer treatment
Date:9/13/2012

Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells. The study is being published this week in PNAS.

Genetically modified T cells (white blood corpuscles) have recently been shown to be extremely effective in treating certain forms of advanced cancer. T cells from the patient's own blood cells are isolated and equipped by genetic means with a new receptor that recognizes an antigen that is expressed in the tumour cells. These T cells are cultivated in a special clean room and then administered to the patient. Once inside the body, they seek out sub tumours and individual tumour cells and eliminate them.

This form of treatment attracted major attention in the world media last autumn when researchers at the University of Pennsylvania, Philadelphia, managed to cure two of three patients with an otherwise incurable form of leukaemia (Kalos et al., Sci Transl Med 3:95ra73, 2011; Porter et al., N Engl J Med 365:725-33, 2011). Trials with genetically modified T-cells have also met with some success in treating malignant melanoma at the National Cancer Institute in Bethesda (Morgan et al., Science 314:126-9, 2006).

Magnus Essand's research team at Uppsala University has now taken the first steps towards making this highly promising form of therapy feasible also for the major public health diseases prostate cancer and breast cancer.

"This is definitely a step along the way to a form of therapy also for our two largest cancer types (prostate cancer and breast cancer)."

Genetically modified T cells are one of two promising avenues the research team is pursuing in order to develop new treatments for cancer. It has taken nearly three years for the scientists to clone the T-cell receptor and then demonstrate its therapeutic capacity.

"This is the first time anyone has succeeded in cloning a T-cell receptor targeting prostate antigen, and we hope we will have an opportunity to test T cells equipped with this receptor in a clinical study. In order to do so, we will probably need to enlist the help of American colleagues," says Victoria Rashkova, who has been involved in the project as part of her doctoral studies.

Every T cell has a unique T-cell receptor, which entails great potential to recognize alien antigens and, for example, kill virus-infected cells. T-cells can also recognize and kill tumour cells, but there aren't enough of them normally to carry out the task. However, if it is known which unique antigen is expressed by a tumour cell type, it should be possible to clone a T-cell receptor that has the capacity to bind to that antigen. This receptor can then be conveyed to the cancer patient's own T cells and used as treatment.


'/>"/>
Contact: Professor Magnus Essand
magnus.essand@igp.uu.se
46-018-611-0223
Uppsala University
Source:Eurekalert

Related medicine news :

1. Eliminating the good cholesterol receptor may fight breast cancer
2. Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved
3. Opioid receptors as a drug target for stopping obesity
4. H1N1 discovery paves way for universal flu vaccine: UBC research
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. Researchers develop a new cell and animal model of inflammatory breast cancer
7. Scientists uncover multiple faces of deadly breast cancer
8. Depo-Provera Birth Control Might Raise Breast Cancer Risk
9. Routine mammograms may result in significant overdiagnosis of invasive breast cancer
10. Mayo Clinic launches whole genome breast cancer study
11. Breast cancer patients suffer treatment-related side effects long after completing care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living ... survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather to ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma ... drugs, biologics, consumer health and global clinical supply services, today announced two key ... the company’s continued investment and strategic growth plans in the Asia Pacific region. ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey ... , The 550 employees of Sun Health Senior Living (SHSL) may not ... reduces their doctor and prescription copays for the year, while holding the line on ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
(Date:5/26/2016)... BELLEVUE, Wash. (PRWEB) , ... May 26, 2016 ... ... a trusted provider of comprehensive treatment for eating disorders, is opening a brand ... facility will provide individuals ages 8-17 and their families with even more specialized ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... CHRISTCHURCH, New Zealand , May 24, 2016 ... scanning and informatics solutions for the healthcare sector, has been ... the New Zealand Hi-Tech Awards 2016. Dr ... a fantastic acknowledgement for our team.  It,s really good to ... the burden healthcare internationally. Our products are used in 35 ...
(Date:5/24/2016)... VMS BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , ... the company,s business development and sales team, exploring new opportunities for VMS to empower ... ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
Breaking Medicine Technology: